No: 2017/SEC/NOV/160

November 20, 2017

National Stock Exchange of India Limited  BSE Limited
“Exchange Plaza”, 5th Floor, Phiroze Jeejeebhoy Towers,
Plot No. C/1, G Block, Dalal Street, Fort,
Bandra-Kurla Complex Mumbai – 400001
Bandra (East), Mumbai – 400051

NSE - Symbol - BIOCON BSE - Scrip code - 532523

Dear Sir,

Sub: Company Statement – “Biocon's Facility receives EIR with VAI status, Inspection Closed.”

Please find below the Company’s statement on the subject matter.

"Biocon confirms that the U.S. Food and Drug Administration (FDA) has issued an Establishment Inspection Report (EIR) in relation to the cGMP (current Good Manufacturing Practice) inspection of its aseptic drug product facility that was audited between 25th May – 3rd Jun 2017. The FDA has classified the outcome of this inspection as VAI (“voluntary action indicated”) and the EIR states that the inspection is closed."

- Company Spokesperson

Kindly take on record the same.

Thanking You,

For BIOCON LIMITED

Rajiv Balakrishnan
Company Secretary